Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,902 total articles
Abbott's share pullback has created an attractive entry for a mid-term swing trade. The company combines durable cash flow - $7.4B in free cash flow - with a conservative balance sheet, a 54-year streak of dividend raises, and near-term catalysts (Exact Sciences acquisition close, new heart-rhythm approval) that can re-rate the multiple. Valuation …
Nebius is rapidly scaling AI-centric cloud infrastructure and building a platform stack that includes data, dev tools, and reskilling. The market is focused on GPUs, but Nebius' $20B+ backlog, a $3B Meta contract, and sky-high growth expectations justify a tactical long swing. Entry $106.08, target $140.00, stop $90.00.
Novo Nordisk plunged to a 52-week low after a disappointing head-to-head obesity trial and aggressive price cuts, but the stock now trades at roughly $169B market cap and a PE near 11. We upgrade to a buy for a tactical swing trade: entry $38.00, stop $34.00, target $52.00 over a mid-term (45 trading days) horizon based on oversold technicals, divi…
Gaming and Leisure Properties (GLPI) offers an attractive entry point for income-focused investors. The REIT yields about 6.46% today, is trading near $48, and has just closed an accretive $700M acquisition and priced an $800M 5.625% note to simplify its capital stack. With solid ROE, positive operating metrics, and indications management is using …
Insteel (IIIN) is a small-cap steel reinforcing products maker showing sustained pricing power and margin upside despite cyclical volume swings. With a market cap of $734,153,740, P/E around 15.4, no debt and improving gross margins, the stock merits a tactical upgrade for a mid-term swing trade. Entry at current levels captures momentum while a co…
MTY Food is an asset-light franchisor with recurring royalties and high free-cash-flow conversion. The shares trade at a single-digit multiple relative to its cash-generative profile. With an upcoming slate of catalysts -- quarterly results, buyback authorization, and margin tailwinds from menu leverage -- this is a mid-term trade to own for income…
Artemis Gold appears to be entering a phase where improving production and robust gold market dynamics can translate into material free cash flow and clearer capital-return options. This trade targets a mid-term swing to capture a re-rating as the company proves operational delivery and moves toward shareholder-friendly uses of cash.
Mercury General screens as a classic insurance recovery trade: manageable balance sheet, strong free cash flow ($990.9M), attractive multiples (EV/EBITDA 6.6, P/E ~11.2), and improving underwriting after a year of elevated catastrophe headlines. I recommend a long entry with a clear stop and a multi-horizon target plan.
CAVA rallied into optimism around new-restaurant growth and industry sentiment, but valuation and cash-flow metrics suggest most upside from openings is already priced. This trade idea recommends a short-swing position sized for conviction: entry $86.00, target $72.00, stop $91.00, horizon mid term (45 trading days).
Equitable's shares trade near the low end of their range after private-credit jitters. The company has meaningful free cash flow, a $1B buyback and recent capital actions that reduce tail risk. We view the current price as a manageable entry for a long trade over a 180 trading-day horizon with a defined stop and a reasonable upside target tied to m…
Netflix has retraced sharply from its 2025 highs and now trades within a stone's throw of the recent $75 low. Fundamentals remain strong - double-digit revenue growth, expanding margins, and a fast-growing ad business - while valuation metrics (EV/EBITDA ~8.9, trailing P/E ~32x) are reasonable relative to growth. This trade idea lays out a clear en…
Accenture has been punished in the market: the stock is down sharply from its 52-week high and momentum indicators are deeply oversold. Yet the business still generates strong free cash flow, sports a 24.7% return on equity, and carries light leverage. This trade idea takes a pragmatic long stance over a mid-term (45 trading days) horizon, using di…
LifeMD (LFMD) is a small-cap telehealth operator priced like a turnaround story but trading with real free cash flow. With a market cap near $132M, EV of roughly $105M and free cash flow of about $10.7M, the stock offers a compelling risk-reward for disciplined traders. This is an actionable long trade with defined entry, stop and target tied to ne…
<p>Costco trades at roughly 53x earnings today, about twice Amazon's P/E. That premium looks large on the surface, but a closer look at Costco's recurring membership income, cash generation, and capital-light balance sheet shows why investors might rationally tolerate a higher multiple. This note upgrades Costco to a buy from a trade perspective an…
Netflix is showing classic operating-leverage dynamics: mid-teens top-line growth, near-30% operating margins and a rapidly scaling ad business. With EV/EBITDA under 9 and free cash flow north of $9.4B, the setup is attractive for a long trade over the next 180 trading days, provided the Warner Bros. deal noise is navigated and macro liquidity rema…
Sinclair’s Q4 beat and a 2026 guide that calls for $700-740M in Adjusted EBITDA plus at least $333M in political advertising revenue shift the risk/reward in favor of buyers. The stock yields north of 7% and generates meaningful free cash flow, providing a margin of safety if secular pressures persist. This trade idea takes a mid-term view to captu…
Farmers & Merchants Bancorp (FMCB) looks like a conservative regional bank trade for 2026: strong earnings, an established dividend track record, and an expanded buyback program support a modest re-rating. Thin liquidity and near-term technical overbought readings argue for a disciplined entry, a modest stop, and a patient long-term horizon.
Diamondback Energy reported mixed Q4 results but generated strong operating cash flow and reiterated a capital-allocation posture that prioritizes debt repayment and shareholder returns. With EV/EBITDA at 6.27 and enterprise value around $65.17B, the stock looks set to re-rate if oil stabilizes and management follows through on buybacks and debt re…
Conagra (CAG) pays an outsized yield (about 7.3%) and trades well below its 52-week high after a stretch of margin pressure and weak organic sales. The company generates solid free cash flow ($876.4M) and trades at a modest P/FCF of 10.4 and EV/EBITDA of 10.4. For dividend-seeking investors willing to tolerate execution risk, an entry near $18.70 w…
Fortune Brands Innovations (FBIN) is a cash-generative building-products conglomerate trading at a reasonable multiple with clear operational catalysts. Conservative guidance has reset expectations and created an entry opportunity; we target $72 with a $50 stop on a long position sized to risk tolerance over the next 180 trading days.
Ceres Power's fuel-cell technology is finding product-market fit beyond traditional CHP applications and into data-center backup and distributed power. We outline a long trade with precise entry, stop and target levels, explain the fundamental case, list near-term catalysts and lay out key risks and a counterargument to our thesis.
Accelerant Holdings (ARX) runs a risk-exchange platform that has shown rapid top-line growth and a move to profitability. The stock sits near its 52-week low while fundamentals, EV-based valuation, and oversold technicals argue for upside. This is a mid-term swing trade idea with a clear entry, stop, and target.
Marfrig Global Foods (MBRFY) looks cheap on headline multiples, yields nearly 12% and is trading above its near-term moving averages. I’m upgrading the rating to a buy for a 2026 earnings recovery trade. Entry near $3.95, target $5.25 and stop $3.10 — plan for a long-term hold into 2026 (up to 180 trading days) while watching margin signals and com…
Gold Royalty (GROY) sits at an interesting crossroads: a leaner balance sheet, an expanded revolving facility, and an accelerating royalty-generator pipeline that has grown to 250 assets. With the stock trading at $4.60 and technicals showing constructive momentum, the risk/reward favors a long exposure to a potential cash-flow inflection and struc…
Equillium is a clinical-stage biotech with a multi-cytokine pipeline anchored by EQ504 (AhR modulation for ulcerative colitis) and complementary assets (EQ001, EQ302). The stock trades around $1.83 with a market cap near $111M and roughly $10.7M in cash. Upcoming UC-focused KOL engagement, partnership work on an oral EQ302 formulation and improving…
